EDITORIAL published: 20 October 2020 doi: 10.3389/fonc.2020.588786 Editorial: PVT1 in Cancer Olorunseun O. Ogunwobi 1* and Miguel F. Segura 2 1 Department of Biological Sciences, Hunter College of The City University of New York, New York, NY, United States, 2 Laboratory of Translational Research in Child and Adolescent Cancer, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca, VHIR, Universitat Autònoma de Barcelona, Barcelona, Spain Keywords: PVT1, cancer, long non-coding RNA, non-coding RNA, chromosome 8q24 Editorial on the Research Topic PVT1 in Cancer The plasmacytoma variant translocation 1 (PVT1) gene is located at human chromosome 8q24, downstream of the well-known c-MYC oncogene (1). As chromosome 8q24 is a chromosomal region of genomic instability, it is not surprising that PVT1 was discovered in the context of cancer. PVT1 is now known to be dysregulated in non-cancerous diseases such as kidney disease (including diabetic nephropathy) (2), cardiac hypertrophy (3), vitiligo (4), osteoarthritis (5), and asthma (6). However, PVT1 is much better established to be dysregulated in a wide variety of cancers including plasmacytomas (7, 8), lymphomas (9, 10), leukemias (11, 12), sarcomas (including osteosarcoma) (13, 14), ovarian cancer (15, 16), breast cancer (16, 17), lung cancer (18, 19), astrocytomas (20), pancreatic cancer (21, 22), prostate cancer (23–26), cholangiocarcinoma (27), gliomas (28), medulloblastoma (29), mesothelioma (30), colorectal cancer (31), gastric cancer (32), hepatocellular carcinoma (33, 34), thyroid cancer (35), bladder cancer (36), renal cell carcinoma (37, 38), cervical cancer (39), esophageal cancer (40), melanoma (41), endometrial cancer (42, 43), non-small cell lung cancer (44, 45), and cutaneous squamous cell carcinoma (46, 47). PVT1 has at least 12 annotated exons: exon 1A, exon 1B, exon 1C, exon 2, exon 3A, exon Edited and reviewed by: 3B, exon 4A, exon 4B, exon 5, exon 6, exon 7, exon 8, and exon 9 (1). And it encodes six Emilio Cusanelli, annotated microRNAs (miRNAs): miR-1204, miR-1205, miR-1206, miR-1207-3p, miR-1207-5p, University of Trento, Italy and miR-1208 (48). PVT1 is expressed in the various organs throughout the human body. There *Correspondence: is progressively increasing evidence that distinct PVT1 exons, and PVT1-encoded miRNAs have Olorunseun O. Ogunwobi significant biological functions, as discussed in the well-written articles included in our Research ogunwobi@genectr.hunter.cuny.edu Topic entitled “PVT1 in Cancer.” In addition, there is evidence of alternative splicing at the PVT1 gene, resulting in at least 25 annotated PVT1 transcript variants (Martinez-Barriocanal et Specialty section: al.). As noted in several of the papers published in the Research Topic “PVT1 in Cancer,” PVT1 This article was submitted to induces cancer development and progression via a variety of biological mechanisms including but Cancer Genetics, not limited to miRNA regulation (Wang et al.), and as a competing endogenous RNA (ceRNA) a section of the journal (Ogunwobi and Kumar). Frontiers in Oncology The articles included in the Research Topic “PVT1 in Cancer” are particularly interesting Received: 29 July 2020 because they highlight the clinical relevance and potential clinical applications of PVT1 in cancer. Accepted: 08 September 2020 For example, the article by Boloix et al. discusses the potential prognostic applications and the Published: 20 October 2020 potential to target PVT1 for therapeutic applications in pediatric cancers. All of the other articles Citation: discuss potential clinical applications in a variety of adult cancers. Notably, Ogunwobi and Kumar Ogunwobi OO and Segura MF (2020) identify PVT1 as a mediator of cancer chemoresistance. Thus, targeting PVT1 may have a future Editorial: PVT1 in Cancer. Front. Oncol. 10:588786. role in the treatment of many highly lethal cancers such as pancreatic cancer, and neuroendocrine doi: 10.3389/fonc.2020.588786 prostate cancer where chemoresistance is common. Frontiers in Oncology | www.frontiersin.org 1 October 2020 | Volume 10 | Article 588786 Ogunwobi and Segura Editorial: PVT1 in Cancer AUTHOR CONTRIBUTIONS FUNDING All authors listed have made a substantial, direct and intellectual OO was supported by National Cancer Institute grant contribution to the work, and approved it for publication. # U54CA221704. REFERENCES 17. Tang J, Li Y, Sang Y, Yu B, Lv D, Zhang W, et al. LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling. Oncogene. 1. Huppi K, Pitt JJ, Wahlberg BM, Caplen NJ. The 8q24 gene desert: an (2018) 37:4723–34. doi: 10.1038/s41388-018-0310-4 oasis of non-coding transcriptional activity. Front Genet. (2012) 3:69. 18. Guo D, Wang Y, Ren K, Han X. Knockdown of LncRNA PVT1 doi: 10.3389/fgene.2012.00069 inhibits tumorigenesis in non-small-cell lung cancer by regulating miR-497 2. Alvarez ML, DiStefano JK. Functional characterization of the plasmacytoma expression. Exp Cell Res. (2018) 362:172–9. doi: 10.1016/j.yexcr.2017.11.014 variant translocation 1 gene (PVT1) in diabetic nephropathy. PLoS ONE. 19. Chen W, Zhu H, Yin L, Wang T, Wu J, Xu J, et al. lncRNA-PVT1 facilitates (2011) 6:e18671. doi: 10.1371/journal.pone.0018671 invasion through upregulation of MMP9 in nonsmall cell lung cancer cell. 3. Yu YH, Hu ZY, Li MH, Li B, Wang ZM, Chen SL. Cardiac hypertrophy is DNA Cell Biol. (2017) 36:787–93. doi: 10.1089/dna.2017.3725 positively regulated by long non-coding RNA PVT1. Int J Clin Exp Pathol. 20. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, et (2015) 8:2582–9. al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of 4. Ben S, Jin Y, Santorico SA, Spritz RA. Genome-wide association of PVT1 with a subset of pediatric malignant astrocytomas. Cancer Res. (2010) 70:512–9. Vitiligo. J Invest Dermatol. (2018) 138:1884–6. doi: 10.1016/j.jid.2018.02.025 doi: 10.1158/0008-5472.CAN-09-1851 5. Li Y, Li S, Luo Y, Liu Y, Yu N. LncRNA PVT1 regulates chondrocyte apoptosis 21. Zhao L, Kong H, Sun H, Chen Z, Chen B, Zhou M. LncRNA-PVT1 promotes in osteoarthritis by acting as a sponge for miR-488-3p. DNA Cell Biol. (2017) pancreatic cancer cells proliferation and migration through acting as a 36:571–80. doi: 10.1089/dna.2017.3678 molecular sponge to regulate miR-448. J Cell Physiol. (2018) 233:4044–55. 6. Austin PJ, Tsitsiou E, Boardman C, Jones SW, Lindsay MA, Adcock IM, et al. doi: 10.1002/jcp.26072 Transcriptional profiling identifies the long noncoding RNA plasmacytoma 22. You L, Wang H, Yang G, Zhao F, Zhang J, Liu Z, et al. Gemcitabine variant translocation (PVT1) as a novel regulator of the asthmatic phenotype exhibits a suppressive effect on pancreatic cancer cell growth by in human airway smooth muscle. J Allergy Clin Immunol. (2017) 139:780–9. regulating processing of PVT1 to miR1207. Mol Oncol. (2018) 12:2147–64. doi: 10.1016/j.jaci.2016.06.014 doi: 10.1002/1878-0261.12393 7. Webb E, Adams JM, Cory S. Variant (6; 15) translocation in a murine 23. Ilboudo A, Chouhan J, McNeil BK, Osborne JR, Ogunwobi OO. PVT1 Exon plasmacytoma occurs near an immunoglobulin kappa gene but far from the 9: a potential biomarker of aggressive prostate cancer? Int J Environ Res Public myc oncogene. Nature. (1984) 312:777–9. doi: 10.1038/312777a0 Health. (2015) 13:ijerph13010012. doi: 10.3390/ijerph13010012 8. Cory S, Graham M, Webb E, Corcoran L, Adams JM. Variant (6;15) 24. Pal G, Huaman J, Levine F, Orunmuyi A, Olapade-Olaopa EO, translocations in murine plasmacytomas involve a chromosome 15 locus Onagoruwa OT, et al. Long noncoding RNA from PVT1 exon 9 is at least 72 kb from the c-myc oncogene. EMBO J. (1985) 4:675–81. overexpressed in prostate cancer and induces malignant transformation doi: 10.1002/j.1460-2075.1985.tb03682.x and castration resistance in prostate epithelial cells. Genes. (2019) 10:964. 9. Huppi K, Siwarski D. Chimeric transcripts with an open reading frame are doi: 10.3390/genes10120964 generated as a result of translocation to the Pvt-1 region in mouse B-cell 25. Orunmuyi A, Ilboudo A, Ogun O, Bach C, Adebayo S, Salako A, et al. PVT1 tumors. Int J Cancer. (1994) 59:848–51. doi: 10.1002/ijc.2910590623 exons 4A, 4B, and 9 are overexpressed in aggressive prostate cancer, and PVT1 10. Graham M, Adams JM. Chromosome 8 breakpoint far 3’ of the c- exon 4B may distinguish between indolent and aggressive prostate cancer. myc oncogene in a Burkitt’s lymphoma 2;8 variant translocation is Cancer Res. (2017) 77 (13 Suppl.):3507. doi: 10.1158/1538-7445.AM2017-3507 equivalent to the murine pvt-1 locus. EMBO J. (1986) 5:2845–51. 26. Pal G, Di L, Orunmuyi A, Olapade-Olaopa EO, Qiu W, Ogunwobi OO. doi: 10.1002/j.1460-2075.1986.tb04578.x Population differentiation at the PVT1 gene locus: implications for prostate 11. Yazdi N, Houshmand M, Atashi A, Kazemi A, Najmedini AA, Zarif MN. cancer. G3 (Bethesda). (2020) 10:2257–64. doi: 10.1534/g3.120.401291 Long noncoding RNA PVT1: potential oncogene in the development 27. Chapman MH, Tidswell R, Dooley JS, Sandanayake NS, Cerec V, of acute lymphoblastic leukemia. Turk J Biol. (2018) 42:405–13. Deheragoda M, et al. Whole genome RNA expression profiling of doi: 10.3906/biy-1801-46 endoscopic biliary brushings provides data suitable for biomarker 12. Zeng C, Yu X, Lai J, Yang L, Chen S, Li Y. Overexpression of discovery in cholangiocarcinoma. J Hepatol. (2012) 56:877–85. the long non-coding RNA PVT1 is correlated with leukemic cell doi: 10.1016/j.jhep.2011.10.022 proliferation in acute promyelocytic leukemia. J Hematol Oncol. (2015) 8:126. 28. Zhang Y, Yang G, Luo Y. Long non-coding RNA PVT1 promotes glioma doi: 10.1186/s13045-015-0223-4 cell proliferation and invasion by targeting miR-200a. Exp Ther Med. (2019) 13. Liu J, Li R, Liao X, Hu B, Yu J. Comprehensive investigation of the 17:1337–45. doi: 10.3892/etm.2018.7083 clinical significance and molecular mechanisms of plasmacytoma variant 29. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, translocation 1 in sarcoma using genome-wide RNA sequencing data. J et al. Subgroup-specific structural variation across 1,000 medulloblastoma Cancer. (2019) 10:4961–77. doi: 10.7150/jca.31675 genomes. Nature. (2012) 488:49–56. doi: 10.1038/nature11327 14. Zhou Q, Chen F, Zhao J, Li B, Liang Y, Pan W, et al. Long non- 30. Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, et coding RNA PVT1 promotes osteosarcoma development by acting as a al. Frequent coamplification and cooperation between C-MYC and PVT1 molecular sponge to regulate miR-195. Oncotarget. (2016) 7:82620–33. oncogenes promote malignant pleural mesothelioma. J Thorac Oncol. (2014) doi: 10.18632/oncotarget.13012 9:998–1007. doi: 10.1097/JTO.0000000000000202 15. Chen Y, Du H, Bao L, Liu W. LncRNA PVT1 promotes ovarian cancer 31. Wu H, Wei M, Jiang X, Tan J, Xu W, Fan X, et al. lncRNA PVT1 promotes progression by silencing miR-214. Cancer Biol Med. (2018) 15:238–50. tumorigenesis of colorectal cancer by stabilizing miR-16-5p and interacting doi: 10.20892/j.issn.2095-3941.2017.0174 with the VEGFA/VEGFR1/AKT axis. Mol Ther Nucleic Acids. (2020) 20:438– 16. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, 50. doi: 10.1016/j.omtn.2020.03.006 Fridlyand J, et al. Amplification of PVT1 contributes to 32. Xu MD, Wang Y, Weng W, Wei P, Qi P, Zhang Q, et al. A positive the pathophysiology of ovarian and breast cancer. Clin feedback loop of lncRNA-PVT1 and FOXM1 facilitates gastric Cancer Res. (2007) 13:5745–55. doi: 10.1158/1078-0432.CCR- cancer growth and invasion. Clin Cancer Res. (2017) 23:2071–80. 06-2882 doi: 10.1158/1078-0432.CCR-16-0742 Frontiers in Oncology | www.frontiersin.org 2 October 2020 | Volume 10 | Article 588786 Ogunwobi and Segura Editorial: PVT1 in Cancer 33. Gou X, Zhao X, Wang Z. Long noncoding RNA PVT1 promotes 43. Kong F, Ma J, Yang H, Yang D, Wang C, Ma X. Long non-coding hepatocellular carcinoma progression through regulating miR-214. Cancer RNA PVT1 promotes malignancy in human endometrial carcinoma cells Biomark. (2017) 20:511–9. doi: 10.3233/CBM-170331 through negative regulation of miR-195-5p. Biochim Biophys Acta. (2018). 34. Lan T, Yan X, Li Z, Xu X, Mao Q, Ma W, et al. Long non-coding RNA doi: 10.1016/j.bbamcr.2018.07.008 PVT1 serves as a competing endogenous RNA for miR-186-5p to promote 44. Cui D, Yu CH, Liu M, Xia QQ, Zhang YF, Jiang WL. Long non-coding RNA the tumorigenesis and metastasis of hepatocellular carcinoma. Tumour Biol. PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung (2017) 39:1010428317705338. doi: 10.1177/1010428317705338 cancer. Tumour Biol. (2016) 37:4127–34. doi: 10.1007/s13277-015-4261-x 35. Zhang R, Hardin H, Huang W, Buehler D, Lloyd RV. Long non-coding 45. Qiu C, Li S, Sun D, Yang S. lncRNA PVT1 accelerates progression of non-small RNA Linc-ROR is upregulated in papillary thyroid carcinoma. Endocr Pathol. cell lung cancer via targeting miRNA-526b/EZH2 regulatory loop. Oncol Lett. (2018) 29:1–8. doi: 10.1007/s12022-017-9507-2 (2020) 19:1267–72. doi: 10.3892/ol.2019.11237 36. Tian Z, Cao S, Li C, Xu M, Wei H, Yang H, et al. LncRNA PVT1 regulates 46. Das Mahapatra K, Pasquali L, Sondergaard JN, Lapins J, Nemeth IB, Baltas growth, migration, and invasion of bladder cancer by miR-31/ CDK1. J Cell E, et al. A comprehensive analysis of coding and non-coding transcriptomic Physiol. (2019) 234:4799–811. doi: 10.1002/jcp.27279 changes in cutaneous squamous cell carcinoma. Sci Rep. (2020) 10:3637. 37. Zou B, Wang D, Xu K, Liu JL, Yuan DY, Meng Z, et al. Prognostic doi: 10.1038/s41598-020-59660-6 value of long non-coding RNA plasmacytoma variant translocation1 47. Wu D, Li Y, Zhang H, Hu X. Knockdown of Lncrna PVT1 enhances in human solid tumors: a meta-analysis. Medicine. (2019) 98:e16087. radiosensitivity in non-small cell lung cancer by sponging Mir-195. Cell doi: 10.1097/MD.0000000000016087 Physiol Biochem. (2017) 42:2453–66. doi: 10.1159/000480209 38. Li W, Zheng Z, Chen H, Cai Y, Xie W. Knockdown of long non-coding RNA 48. Huppi K, Volfovsky N, Runfola T, Jones TL, Mackiewicz M, Martin PVT1 induces apoptosis and cell cycle arrest in clear cell renal cell carcinoma SE, et al. The identification of microRNAs in a genomically unstable through the epidermal growth factor receptor pathway. Oncol Lett. (2018) region of human chromosome 8q24. Mol Cancer Res. (2008) 6:212–21. 15:7855–63. doi: 10.3892/ol.2018.8315 doi: 10.1158/1541-7786.MCR-07-0105 39. Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, Rader JS. The lncRNA PVT1 contributes to the cervical cancer phenotype and Conflict of Interest: OO is a co-founder of NucleoBio, Inc., a City University of associates with poor patient prognosis. PLoS ONE. (2016) 11:e0156274. New York start-up biotechnology company. doi: 10.1371/journal.pone.0156274 40. Li PD, Hu JL, Ma C, Ma H, Yao J, Chen LL, et al. Upregulation of the The remaining author declares that the research was conducted in the absence of long non-coding RNA PVT1 promotes esophageal squamous cell carcinoma any commercial or financial relationships that could be construed as a potential progression by acting as a molecular sponge of miR-203 and LASP1. conflict of interest. Oncotarget. (2017) 8:34164–76. doi: 10.18632/oncotarget.15878 41. Chen L, Ma D, Li Y, Li X, Zhao L, Zhang J, et al. Effect of long non-coding Copyright © 2020 Ogunwobi and Segura. This is an open-access article distributed RNA PVT1 on cell proliferation and migration in melanoma. Int J Mol Med. under the terms of the Creative Commons Attribution License (CC BY). The use, (2018) 41:1275–82. doi: 10.3892/ijmm.2017.3335 distribution or reproduction in other forums is permitted, provided the original 42. Xing TR, Chen P, Wu JM, Gao LL, Yang W, Cheng Y, et al. UPF1 participates in author(s) and the copyright owner(s) are credited and that the original publication the progression of endometrial cancer by inhibiting the expression of lncRNA in this journal is cited, in accordance with accepted academic practice. No use, PVT1. Onco Targets Ther. (2020) 13:2103–14. doi: 10.2147/OTT.S233149 distribution or reproduction is permitted which does not comply with these terms. Frontiers in Oncology | www.frontiersin.org 3 October 2020 | Volume 10 | Article 588786